TABLE 1.

Demographic data of the study sample

	All patients (n = 17)
Age, year, median (range)	36 (25–65)
Sex, F/M	7/10
MS phenotype (RRMS/MS)	11/6
Baseline disease duration, year, median (range)	3.4 (0.3–28)
Baseline EDSS, median (range)	2.5 (1–6.5)
Baseline number of relapses, median (range)	RRMS: 2 (1–5)	PMS: N/A
Disease‐modifying treatment	RRMS: first line, n: 5 second line, n: 6	PMS: ocrelizumab, n: 2 none, n: 4